Overview

Basic information

Litigation

Active legal matters

Material Events

8-K disclosures

SEC Filings

Key regulatory docs

Insider Transactions

Ownership changes

Overview

Basic information

Litigation

Active legal matters

Material Events

8-K disclosures

SEC Filings

Key regulatory docs

Insider Transactions

Ownership changes

Zenas BioPharma, Inc. (ZBIO) Class Action Lawsuit (April 2025)

Closed

1:25cv10988 • April 16, 2025

Class Period Start

September 13, 2024

Class Period End

April 16, 2025

PSLRA Deadline

June 16, 2025

Case Allegations

Sec11

Statutes of Repose

Sep 13, 2027

Country

United States

Court

Federal Court

Docket History

Aug 3, 2026

No Appeal- Closed

Jun 29, 2026

Motion to Dismiss Granted

The court has granted the defendants' request to dismiss the lawsuit. Depending on the court's decision, the plaintiffs may be allowed to file an updated complaint or pursue an appeal.

Jan 23, 2026

Motion to Dismiss

After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.

Nov 21, 2025

First Amended Complaint

A new complaint has been filed on behalf of certain investors in Zenas BioPharma, Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.

Aug 21, 2025

Appointment of Lead Plaintiff

The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.

Apr 16, 2025

First Filed Complaint

A securities fraud class action complaint has been filed on behalf of certain investors in Zenas BioPharma, Inc..

TOP